Business Overview: Nurix Therapeutics, Inc. (NASDAQ: NRIX)

---

Executive Summary

Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Brisbane, California, focused on targeted protein degradation (TPD) medicines for cancer and inflammatory diseases. Rather than inhibiting a disease-causing protein the way a traditional small-molecule drug does, Nurix's degrader medicines are designed to eliminate the target protein entirely by hijacking the body's own protein-disposal machinery — a mechanism that can address disease targets conventional drugs cannot reach.

Nurix's DEL-AI platform — combining DNA-encoded library (DEL) screening with machine learning — is the engine behind both its wholly-owned pipeline and a set of high-value pharma collaborations with Gilead, Sanofi, and Pfizer (via Seagen), which together had delivered $482.0 million in collaboration funding through November 30, 2025, with up to $6.1 billion in potential future fees, milestones, and royalties still on the table.

---

1. Core Business Model & How They Work

[ DEL-AI Platform: DNA-Encoded Library Screening + Machine Learning ]
        ➡️ [ Hit-Finding & Degrader Design ] ➡️ [ Automated Chemistry & Screening ]
        ➡️ [ Wholly-Owned Clinical Pipeline ]   or   [ Partnered Programs (Gilead, Sanofi, Pfizer/Seagen) ]
        ➡️ [ Clinical Development ] ➡️ [ Regulatory Approval ] ➡️ [ Commercialization / Milestones & Royalties ]

Key Operational Drivers

1. Platform-driven discovery at scale: The DEL-AI platform's library holds approximately 5 billion compounds, and the company has screened against more than 100 E3 ligases — the "garbage disposal" enzymes that degrader drugs hijack — giving Nurix a large, systematic search space for new degrader targets.
2. Dual revenue model: Nurix funds continued R&D both through its own balance sheet (for wholly-owned programs) and through non-dilutive collaboration funding from large pharma partners, who pay upfront and milestone fees for rights to specific targets.
3. Clinical-stage de-risking through partnerships: By partnering select targets (e.g., an IRAK4 degrader with Gilead, a STAT6 degrader licensed to Sanofi) while retaining its most advanced, highest-conviction programs (bexobrutideg, zelebrudomide) wholly owned, Nurix balances risk and retained upside.

---

2. Pipeline

---

3. Partnerships

• Gilead — collaboration since 2019, covering up to five targets, including the clinical-stage IRAK4 degrader program.
• Sanofi — collaboration since 2019/2020 across multiple targets, including the STAT6 development candidate licensed in June 2025.
• Pfizer (via its Seagen acquisition) — a degrader-antibody-conjugate (DAC) focused collaboration since September 2023.

Collectively, these partnerships had generated $482.0 million in collaboration funding through November 30, 2025, with up to $6.1 billion in further potential fees, milestones, and royalties — a substantial non-dilutive funding and validation source for a clinical-stage company.

---

4. Strategic Strengths & Risks

Strengths

• Validated discovery platform: Three major pharma partnerships (Gilead, Sanofi, Pfizer) for a technology platform is a strong external signal that DEL-AI produces genuinely differentiated, licensable assets.
• Dual regulatory designations on lead asset: Bexobrutideg's combination of FDA Fast Track and EMA PRIME designations suggests regulators see meaningful unmet need in its target indications (CLL/SLL, Waldenström's).
• Large, systematic screening capacity: A ~5 billion compound DEL library screened against 100+ E3 ligases gives Nurix a wide discovery funnel relative to smaller or narrower TPD competitors.
• Non-dilutive funding cushion: $482 million in collaboration funding received to date reduces reliance on dilutive equity financing to fund the wholly-owned pipeline.

Risks

• Clinical-stage, pre-revenue company: Like essentially all clinical-stage biotechs, Nurix has no approved products and remains dependent on trial outcomes, with bexobrutideg and zelebrudomide both still in early-to-mid-stage trials.
• Manufacturing/regulatory setbacks are real and have occurred: Zelebrudomide's Phase 1a/1b was partially clinically held in 2023 over a manufacturing change — a reminder that even advanced-stage degrader programs carry real execution risk.
• Competitive and crowded TPD field: Targeted protein degradation has attracted substantial capital and competition from other platform companies and large pharma internal programs, all pursuing overlapping degrader targets.
• Partner concentration: A meaningful share of near-term non-dilutive funding and validation is concentrated in three large pharma relationships (Gilead, Sanofi, Pfizer); any one partner discontinuing a collaboration would be a material setback.

---

5. Financial Overview

(Cash balance and R&D spend were not captured in the Item 1 excerpt reviewed; the financial statements in the full 10-K would refine the runway picture.)

---

6. Summary Conclusion

Nurix Therapeutics has built one of the more credibly validated targeted protein degradation platforms in biotech, evidenced by $482 million in collaboration funding and up to $6.1 billion in potential further payments across partnerships with Gilead, Sanofi, and Pfizer — a strong external endorsement of its DEL-AI discovery engine. Its lead wholly-owned asset, bexobrutideg, carries both FDA Fast Track and EMA PRIME designations and has advanced into Phase 2 in CLL/SLL. The central risk is the one inherent to all clinical-stage biotechs: none of Nurix's programs are approved or revenue-generating yet, and the 2023 manufacturing-related clinical hold on zelebrudomide is a concrete reminder that even well-funded, well-partnered degrader programs can hit real development setbacks before reaching the market.